Clinical Trial Update: The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma [Phase 1]

View source ↗

Summary

An ongoing Phase 1 trial of CC-1, a PSMAxCD3 bispecific antibody, for castration-resistant prostate cancer, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CC-1 (PSMAxCD3 bispecific antibody)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Castration-Resistant Prostatic Cancer | Phase 1 | Status: RECRUITING